This is the second post in our series on xenon therapy’s effects in Alzheimer’s disease models. While our first post examined xenon-driven changes in microglial activation states, this post focuses specifically on how xenon affects amyloid plaque pathology and the neuronal damage surrounding these plaques.
Why Plaque Structure Matters Beyond Burden?
When evaluating xenon’s effects on Alzheimer’s pathology, reducing amyloid isn’t simply about decreasing the totalamount of plaques. The way microglia manage these plaques matters just as much as how many they clear. Microglia can limit Aβ toxicity through two distinct mechanisms: by reducing the overall plaque burden through phagocytosis, and by physically compacting existing plaques into denser, more contained structures. This compaction process effectively sequesters toxic aggregates away from nearby neurons, reducing their harmful impact on surroundingbrain tissue. Understanding this dual role of microglia as both clearance agents and structural managers became central to explaining how xenon achieves its therapeutic effects in Alzheimer’s disease.
Experimental Design
The team treated APP/PS1 mice (a canonical amyloid mouse model) with 30% xenon for 40 minutes once weekly,starting at 2 months of age when amyloid deposition begins, continuing for 8 weeks total. They measured two key markers of plaque pathology:
- Aβ plaques: Detected using 4B antibody staining, a specialized marker that binds to amyloid-beta deposits and makes them visible under microscopy
- Dystrophic neurites: Quantified as Lamp1-positive area around plaques, serving as the direct measure of plaque-adjacent neuronal damage
Plaques were also stratified by size to determine where xenon’s effects concentrated.
Key Finding 1: Enhanced Plaque Compaction
After two months of weekly xenon inhalation, something remarkable happened in the brains of APP/PS1 mice. The amyloid plaques that characterize Alzheimer’s disease became more compact and contained, with more microglial coverage per plaque and a shift toward fewer, larger plaques. These changes are consistent with xenon promotingdenser, more consolidated plaque structures.
The numbers backed this up. Quantitative analysis showed a significant decrease in
plaque-associated Aβ area (P = 0.0452), increased microglial coverage around plaques, and a shift toward larger, more compact plaque structures. But why does compaction matter?
The answer lies in how microglia manage amyloid toxicity. These brain immune cells can tackle the problem in twoways: by engulfing and degrading plaques to reduce the total burden, and by physically compacting existing plaques to keep toxic proteins away from vulnerable neurons.
Xenon appears to enhance both strategies.
Key Finding 2: Reduced Neuritic Dystrophy
The structural changes translated into real neuroprotection. When the team used confocal imaging to examine thetissue around plaques, they found significantly less neuronal damage in xenon-treated mice. They measured this using Lamp1-positive dystrophic neurites, a marker that reveals injured neurons, and discovered both a lower percentage of damaged area per plaque and fewer plaques showing any neuronal injury at all.
Interestingly, the protective effect wasn’t uniform across all plaques. Larger plaques (those above 250 μm²)showed the most dramatic reduction in surrounding neuronal damage. This size-dependent effect is particularlymeaningful because larger plaques typically inflict more extensive damage on surrounding tissue. Xenon’s abilityto mitigate injury at these high-risk sites suggests a targeted neuroprotective mechanism.
What’s driving this protection? The study found that xenon treatment shifted microglial gene expression away from inflammatory, disease-associated profiles and toward protective programs linked to synaptogenesis. Thistranscriptional reprogramming appears to be key to xenon’s therapeutic effects.
Mechanistic Support: Enhanced Aβ Phagocytosis
To understand the cellular mechanism behind these improvements, the researchers directly tested whether xenonenhanced microglia’s ability to handle amyloid. They injected fluorescent Aβ(1-42) into mice after xenon exposure and used flow cytometry to track what happened.
The results were clear: xenon-treated mice showed both a higher percentage of microglia that successfully phagocytosed amyloid and greater amounts of amyloid consumed per individual microglial cell. This enhanced cleanup capacity provides a satisfying explanation for why plaques became more compact and why neurons suffered less damage.
Validation Across Multiple Amyloid Models
To establish the generalizability of their findings, the team validated xenon’s effects in two additional amyloid models, each designed to test a specific aspect of the therapeutic mechanism.
5xFAD Model: Myeloid Cell Dependency
In 5xFAD mice (which develop amyloid pathology more aggressively than APP/PS1 mice), the researchers used a drug called PLX-5622 to deplete brain myeloid cells, primarily microglia.
With brain myeloid cells depleted, xenon’s ability to reduce cortical plaque load and
Lamp1-positive dystrophic neurites was lost. This strongly supports the idea that xenon acts through microglia and otherbrain myeloid cells rather than by directly interacting with amyloid proteins.
Importantly, it was observed that whole-brain measurements of soluble and insoluble Aβ levels were not altered despite the cortical histology changes. This suggests xenon’s effects are regionally specific, reorganizing how amyloid distributes in the brain rather than reducing total production or enhancing systemic clearance.
5x-MITRG Model: Human Microglia Validation
To assess relevance to human biology, the team used 5x-MITRG mice engrafted with human iPSC-derivedmicroglia. Xenon inhalation in this humanized model reproduced the therapeutic effects observed with mouse microglia, with improvements distributed across both cortex and hippocampus. This cross-species consistency strengthens the translational potential for developing xenon therapy for human Alzheimer’s disease.
Conclusion
This research demonstrates that xenon can reduce amyloid pathology in Alzheimer’s disease through a microglialmechanism. Rather than simply clearing plaques, xenon promotes plaque compaction and protects neurons from damage in the areas surrounding amyloid deposits.
The findings establish several important points. First, xenon’s effects require the presence of microglia, confirming it works by modulating the brain’s immune response rather than directly targeting amyloid. Second, the therapeutic benefits replicate across multiple experimental models, demonstrating consistency. Most notably, human microglia engrafted into 5x-MITRG mice respond to xenon with the same pattern of plaque compaction and reduced neuritic dystrophy seen with mouse microglia, strengthening the translational potential of these findings.
The study shows that weekly xenon inhalation over two months can shift microglial function toward protective programs,enhance their ability to manage toxic amyloid, and reduce neuronal injury around plaques. These results position xenon as a therapeutic candidate that addresses both the structural presence of amyloid pathology and the neuronal damage it causes.
Reference:
Wesley Brandao, Nimansha Jain, et al. Inhaled xenon modulates microglia and ameliorates disease in mouse models of amyloidosis and tauopathy. Sci. Transl. Med.17, eadk3690(2025). DOI:10.1126/scitranslmed.adk3690